Sign In
Buy NTLA
$13.02
-1.20 (-8.41%)
At Close: Jul 13, 2026
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
11:21am, Thursday, 09'th Jul 2026
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
05:45am, Wednesday, 08'th Jul 2026
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 06'th Jul 2026
CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
03:45pm, Wednesday, 01'st Jul 2026
It might pull it off, provided several things fall right in place.
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
10:35am, Monday, 29'th Jun 2026
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if s
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
11:02am, Saturday, 20'th Jun 2026
Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FD
Dow Extends Record Run as Fed Decision Looms
12:03pm, Wednesday, 17'th Jun 2026
Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once again
This Stock Is Up 58% This Year. Is It too Late to Buy?
02:30am, Wednesday, 17'th Jun 2026
There could be additional catalysts for this drugmaker over the next year.
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
11:20am, Tuesday, 16'th Jun 2026
Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
09:45am, Tuesday, 16'th Jun 2026
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
09:39am, Monday, 15'th Jun 2026
Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is trading higher on Monday on additional positive findings from its global Phase 3 HAELO trial evaluating lonvo-z, its investigational CRISPR-based tre
CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
12:31pm, Wednesday, 10'th Jun 2026
Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock?
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Jun 2026
CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
